Tuberculosis

Tuberculosis

WHO / Yoshi Shimizu

Tuberculosis (TB) remains a major cause of illness and death among children worldwide. Every year, more than 1 million children and young adolescents aged under 15 years of age are estimated to develop TB, and more than 150,000 die from the disease, with the highest mortality burden among children under five years of age. Despite progress in TB prevention and treatment, important gaps remain in access to effective, safe, and child-friendly medicines, particularly for the youngest children and those with drug-resistant TB.

With an increasingly rich and diverse pipeline of new TB medicines and treatment regimens, there is an unprecedented opportunity to proactively guide paediatric drug development, providing early signals to developers on priority paediatric populations, study requirements, and optimal formulation characteristics.

Building on previous PADO-TB exercises, the WHO Paediatric Drug Optimization (PADO) process in September/October 2026, held alongside the first CADO meeting for TB, aimed to identify priority needs and inform the development of optimized TB medicines for children of all ages. The joint CADO/PADO pipeline review informed priorities across age groups, supporting timely and equitable access to new treatments for children of all ages.

Portfolio products

7 products · PADO-TB
● Access list: 0    ● Priority list: 4    ● Watch list: 3
0 Access
4 Priority
3 Watch

PADO-TB priority list 4
Rifapentine
150 mg scored dispersible tablet
Rifampicin (tentative listing)
100 mg scored dispersible tablet
Moxifloxacin
100 mg dispersible tablet (palatable)
Pretomanid
PADO-TB watch list 3
All compounds in or shortly entering phase II
With special attention to compounds that are more advanced in development (phase IIb/c), including delpazolid, sutezolid, GSK-656, quabodepistat, BTZ-043 and TBI-223.
Long-acting technologies
(e.g. injectables, microarray patches) for TB medicines.
Oral dispersible film/strips of rifapentine-including products.
Portfolio Update
  • Meeting reports summarizing key discussions, outcomes, and priorities will be made available by Q1 2027.

PADO report

Paediatric drug optimization for tuberculosis: meeting report, October 2023
Paediatric drug optimization (PADO) exercises have been convened by the World Health Organization (WHO) for various diseases, demonstrating their potential...

Contact

Sabine Verkuijl
Email: verkuijls@who.int

Related publications

Global tuberculosis report 2026

The WHO Global tuberculosis report 2026 provides a comprehensive assessment of the tuberculosis (TB) epidemic and progress in prevention, diagnosis and...

Roadmap towards ending TB in children and adolescents, 3rd ed

The Roadmap towards ending TB among children and adolescents, third edition builds on the 2013 and 2018 versions. The 2023 version recognizes the progress...

Related links

News